Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
A major driver for the recent investment surge in bispecific antibody (bsAb) platforms and products is the multitude of distinct mechanisms of action that bsAbs offer compared to a combination of two monoclonal antibodies. Four bsAb products were granted first regulatory approvals in the US or EU du...
| Main Authors: | , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Taylor & Francis Group
2024-12-01
|
| 丛编: | mAbs |
| 主题: | |
| 在线阅读: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2311992 |